MathesonJ, TertigasD, MalikS, et al.Feasibility and tolerability of nabilone for the treatment of obesity: A Randomized Controlled Pilot Trial. Cannabis Cannabinoid Res, 2025; doi: 10.1089/can.2025.0034
2.
NdumeleCE, RangaswamiJ, ChowSL, et al.; American Heart Association. Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association. Circulation, 2023; 148(20):1606–1635; doi: 10.1161/CIR.0000000000001184
3.
MalikS, WongND, FranklinSS, et al.Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 2004; 110(10):1245–1250; doi: 10.1161/01.CIR.0000140677.20606.0E
4.
Hugh WatersB, GrafM. America’s obesity crisis the health and economic costs of excess weight. Milken Institute; 2018.
5.
Osei-HyiamanD, DePetrilloM, PacherP, et al.Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest, 2005; 115(5):1298–1305; doi: 10.1172/JCI200523057
6.
KirkhamTC, WilliamsCM, FezzaF, et al.endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol, 2002; 136(4):550–557; doi: 10.1038/sj.bjp.0704767
7.
JamshidiN, TaylorDA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol, 2001; 134(6):1151–1154; doi: 10.1038/sj.bjp.0704379
8.
MatiasI, GonthierMP, OrlandoP, et al.Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab, 2006; 91(8):3171–3180; doi: 10.1210/jc.2005-2679
9.
DesprésJ-P, GolayA, SjöströmL, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med, 2005; 353(20):2121–2134; doi: 10.1056/nejmoa044537
10.
JbiloO, Ravinet-TrillouC, ArnoneM, et al.The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. Faseb J, 2005; 19(11):1567–1569; doi: 10.1096/fj.04-3177fje
11.
LipinaC, VaanholtLM, DavidovaA, et al.CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction. Aging Cell, 2016; 15(2):325–335; doi: 10.1111/acel.12438
12.
WangQ, PerrardXD, PerrardJL, et al.Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity. Obesity (Silver Spring), 2011; 19(3):505–513; doi: 10.1038/oby.2010.213
13.
HayatbakhshMR, O’CallaghanMJ, MamunAA, et al.Cannabis use and obesity and young adults. Am J Drug Alcohol Abuse, 2010; 36(6):350–356; doi: 10.3109/00952990.2010.500438
14.
RossJM, Pacheco-ColónI, HawesSW, et al.Bidirectional longitudinal associations between cannabis use and body mass index among adolescents. Cannabis Cannabinoid Res, 2020; 5(1):81–88; doi: 10.1089/can.2019.0091
15.
Le StratY, Le FollB. Obesity and cannabis use: Results from 2 representative national surveys. Am J Epidemiol, 2011; 174(8):929–933; doi: 10.1093/aje/kwr200
16.
RodondiN, PletcherMJ, LiuK, et al.; Coronary Artery Risk Development in Young Adults (CARDIA) Study. Marijuana use, diet, body mass index, and cardiovascular risk factors (from the CARDIA Study). Am J Cardiol, 2006; 98(4):478–484; doi: 10.1016/j.amjcard.2006.03.024
17.
SmitE, CrespoCJ. Dietary intake and nutritional status of US adult marijuana users: Results from the Third National Health and Nutrition Examination Survey. Public Health Nutr, 2001; 4(3):781–786; doi: 10.1079/phn2000114
18.
FoltinRW, FischmanMW, ByrneMF. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite, 1988; 11(1):1–14.
19.
HargreavesM, SprietLL. Skeletal muscle energy metabolism during exercise. Nat Metab, 2020; 2(9):817–828; doi: 10.1038/s42255-020-0251-4
20.
HorswillJG, BaliU, ShaabanS, et al.PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB 1 receptors with hypophagic effects in rats. Br J Pharmacol, 2007; 152(5):805–814; doi: 10.1038/sj.bjp.0707347
21.
DalleS, SchoutenM, DeboutteJ, et al.The molecular signature of the peripheral cannabinoid receptor 1 antagonist AM6545 in adipose, liver and muscle tissue. Toxicol Appl Pharmacol, 2024; 491:117081; doi: 10.1016/j.taap.2024.117081
22.
DalleS, SchoutenM, RamaekersM, et al.The cannabinoid receptor 1 antagonist AM6545 stimulates the Akt-mTOR axis and in vivo muscle protein synthesis in a dexamethasone-induced muscle atrophy model. Mol Cell Endocrinol, 2023; 563:111854.
23.
BisognoT, MahadevanA, CoccurelloR, et al.A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects. Br J Pharmacol, 2013; 169(4):784–793.
24.
HaneyM, ValléeM, FabreS, et al.Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: Phase 1 and phase 2a randomized trials. Nat Med, 2023; 29(6):1487–1499; doi: 10.1038/s41591-023-02381-w
